Monz takes over as ceo of Carl Zeiss Meditec

Ludwin Monz has been named as chief executive of Carl Zeiss Meditec.

Ludwin Monz has been named as chief executive of Carl Zeiss Meditec. He takes over from Michael Kaschke, who resumes his role as chairman of the company's supervisory board.

Monz has been a member of Carl Zeiss Meditec's management board since October 2007 and is responsible for the firm's Ophthalmological Systems division. Prior to this he led the Microsurgery division for six years.

With a doctorate in physics and an MBA, Monz joined the Carl Zeiss Group in 1994 and has worked in medical technology since 2000.

You may also like

Analysis

IMPACT CKD model reveals the escalating toll of chronic kidney disease

The model projects up to 125 million of the population across eight countries to suffer from chronic kidney disease by 2032
Analysis

Landmark installation for the Vapourtec E-Series system

The landmark spreads the use of E-Series to 20 nations and comes in four standard configurations: easy-Scholar, easy-Polymer, easy-Medchem and easy-Photochem
Digital

Qinecsa Solutions acquires Insife to expand its pharmacovigilance technology solutions

The HALOPV platform developed by Insife is considered a safety database with multivigilance capabilities and more, as it covers the end-to-end management of PV processes
Digital

Real-time data insights powered by digital transformation

The most trailblazing contract development and manufacturing organisations (CDMOs) are at the forefront of digital transformation, leveraging it to offer unparalleled customer service through operational streamlining and the provision of insights
Manufacturing

The future of industrial automation in chemicals

The chemical industry is a large and diverse sector that manufactures a wide range of products, including fibres, plastics, surface finishes and pharmaceutical excipients. Agriculture, construction, transportation, healthcare and consumer goods are just a few sectors that use such chemical products
Research & Development

SimBioSys and General Inception partner to accelerate cancer drug development

PhenoScope, SimBioSys' proprietary digital technology, can cut drug development time and costs significantly
Manufacturing

Implementing a “low/no code” automated process control system

Never before has the world seen such great progress in digital technology; we are at the forefront of breakthrough innovations, systems and processes that are facilitating the development of incredible products for our communities. Yet, with these advances, many companies in the life sciences and pharmaceutical industries are experiencing growth pains
Subscribe now